Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.
Erdafitinib
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results. ### Output: Erdafitinib